Novel breakthroughs in advanced prostate cancer management.

Local radiotherapy has proven to be a game changer for low burden, de novo metastatic prostate cancer. Androgen deprivation therapy continues to be the ultimate treatment. Delaying resistance to these agents will undoubtedly be a breakthrough in the treatment of prostate cancer. When it comes to metastatic castrate resistant disease, treatment options become narrower. PARP inhibitors and N-terminal domain inhibitors, offer new hope, and have a synergistic effect with immunotherapy adding promising agents to the therapeutic arsenal.